PMID- 22886490
OWN - NLM
STAT- MEDLINE
DCOM- 20130218
LR  - 20220330
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 139
IP  - 1
DP  - 2013 Jan
TI  - Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
PG  - 39-48
LID - 10.1007/s00432-012-1298-8 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) could be used as potential cellular adjuvant 
      for the production of specific tumor vaccines. OBJECTIVES: Our study was aimed to 
      evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced 
      hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. 
      METHODS: Thirty patients with advanced HCC not suitable for radical or 
      loco-regional therapies were enrolled. Patients were divided into 2 groups, group 
      I consisted of 15 patients received I.D vaccination with mature autologous DCs 
      pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 
      15) received supportive treatment. One hundred and 4 ml of venous blood were 
      obtained from each patient to generate DCs. DCs were identified by CD80, CD83, 
      CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months 
      post injection by clinical, radiological and laboratory assessment was done. 
      RESULTS: Improvement in overall survival was observed. Partial radiological 
      response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) 
      and 4 patients (26.7 %) showed progressive disease (died at 4 months 
      post-injection). Both CD8(+) T cells and serum interferon gamma were elevated 
      after DCs injection. CONCLUSION: Autologous DC vaccination in advanced HCC 
      patients is safe and well tolerated.
FAU - El Ansary, Mervat
AU  - El Ansary M
AD  - Department of Clinical Pathology, Kasr Al-Aini, Cairo University, Cairo, Egypt.
FAU - Mogawer, Sherif
AU  - Mogawer S
FAU - Elhamid, Samah Abd
AU  - Elhamid SA
FAU - Alwakil, Sahr
AU  - Alwakil S
FAU - Aboelkasem, Fatma
AU  - Aboelkasem F
FAU - Sabaawy, Hatem El
AU  - Sabaawy HE
FAU - Abdelhalim, Olfat
AU  - Abdelhalim O
LA  - eng
GR  - P30 CA072720/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120812
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cancer Vaccines)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Carcinoma, Hepatocellular/blood/complications/diagnostic 
      imaging/*immunology/*therapy
MH  - Dendritic Cells/*immunology
MH  - Disease Progression
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - Hepatic Encephalopathy/etiology/prevention & control
MH  - Humans
MH  - Immunotherapy/adverse effects/*methods
MH  - Interferon-gamma/blood
MH  - Liver Function Tests
MH  - Liver Neoplasms/blood/complications/diagnostic imaging/*immunology/*therapy
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Palliative Care/methods
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Transplantation, Autologous
MH  - Treatment Outcome
PMC - PMC5223882
MID - NIHMS839883
COIS- The authors declare no conflicts of interest.
EDAT- 2012/08/14 06:00
MHDA- 2013/02/19 06:00
PMCR- 2017/01/10
CRDT- 2012/08/14 06:00
PHST- 2012/05/29 00:00 [received]
PHST- 2012/07/26 00:00 [accepted]
PHST- 2012/08/14 06:00 [entrez]
PHST- 2012/08/14 06:00 [pubmed]
PHST- 2013/02/19 06:00 [medline]
PHST- 2017/01/10 00:00 [pmc-release]
AID - 10.1007/s00432-012-1298-8 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2013 Jan;139(1):39-48. doi: 10.1007/s00432-012-1298-8. 
      Epub 2012 Aug 12.